104 related articles for article (PubMed ID: 9143404)
1. Soluble CD44 variants in the serum of patients with urological malignancies.
Lein M; Jung K; Weiss S; Schnorr D; Loening SA
Oncology; 1997; 54(3):226-30. PubMed ID: 9143404
[TBL] [Abstract][Full Text] [Related]
2. Soluble CD44 molecules in serum of patients with prostate cancer and benign prostatic hyperplasia.
Jung K; Lein M; Weiss S; Schnorr D; Henke W; Loening S
Eur J Cancer; 1996 Apr; 32A(4):627-30. PubMed ID: 8695265
[TBL] [Abstract][Full Text] [Related]
3. Soluble CD44 v5 and v6 in serum of patients with breast cancer. Correlation with expression of CD44 v5 and v6 variants in primary tumors and location of distant metastasis.
Lackner C; Moser R; Bauernhofer T; Wilders-Truschnig M; Samonigg H; Berghold A; Zatloukal K
Breast Cancer Res Treat; 1998 Jan; 47(1):29-40. PubMed ID: 9493973
[TBL] [Abstract][Full Text] [Related]
4. Serological evaluation of soluble CD44 in renal cancer.
Kan M; Kanayama H; Naruo S; Tsuji M; Kojima K; Kurokawa Y; Kagawa S
Jpn J Cancer Res; 1996 Nov; 87(11):1191-4. PubMed ID: 9045950
[TBL] [Abstract][Full Text] [Related]
5. Serum assay of soluble CD44 standard (sCD44-st), CD44 splice variant v5 (sCD44-v5), and CD44 splice variant v6 (sCD44-v6) in patients with epithelial ovarian cancer.
Gadducci A; Ferdeghini M; Fanucchi A; Annicchiarico C; Cosio S; Prontera C; Bianchi R; Genazzani AR
Anticancer Res; 1997; 17(6D):4463-6. PubMed ID: 9494551
[TBL] [Abstract][Full Text] [Related]
6. Soluble CD44 isoforms in serum as potential markers of metastatic gastric carcinoma.
Harn HJ; Ho LI; Shyu RY; Yuan JS; Lin FG; Young TH; Liu CA; Tang HS; Lee WH
J Clin Gastroenterol; 1996 Mar; 22(2):107-10. PubMed ID: 8742647
[TBL] [Abstract][Full Text] [Related]
7. Soluble CD44 splice variants and pelvic lymph node metastasis in ovarian cancer patients.
Stickeler E; Vogl FD; Denkinger T; Mobus VJ; Kreienberg R; Runnebaum IB
Int J Mol Med; 2000 Nov; 6(5):595-601. PubMed ID: 11029531
[TBL] [Abstract][Full Text] [Related]
8. The serum assay of soluble CD44 standard (sCD44-st), CD44 splice variant 5 (sCD44-v5), and CD44 splice variant 6 (sCD44-v6) in patients with cervical cancer.
Gadducci A; Ferdeghini M; Cosio S; Annicchiarico C; Fanucchi A; Prontera C; Bianchi R; Genazzani AR
Anticancer Res; 1998; 18(1B):537-9. PubMed ID: 9568174
[TBL] [Abstract][Full Text] [Related]
9. Elevated serum levels of soluble CD44 variant 6 are correlated with shorter survival in aggressive non-Hodgkin's lymphoma.
Sasaki K; Niitsu N
Eur J Haematol; 2000 Sep; 65(3):195-202. PubMed ID: 11007056
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-1 alpha and interleukin-1 beta production in peripheral whole blood from patients with urological cancer.
Kuo JY; Ohmoto Y; Yoshida O
Hinyokika Kiyo; 1998 Jun; 44(6):397-402. PubMed ID: 9719938
[TBL] [Abstract][Full Text] [Related]
11. Expression of CD44 isoforms in human renal cell carcinomas.
Heider KH; Ratschek M; Zatloukal K; Adolf GR
Virchows Arch; 1996 Jul; 428(4-5):267-73. PubMed ID: 8764936
[TBL] [Abstract][Full Text] [Related]
12. High serum levels of soluble CD44 variant isoform v5 are associated with favourable clinical outcome in ovarian cancer.
Zeimet AG; Widschwendter M; Uhl-Steidl M; Müller-Holzner E; Daxenbichler G; Marth C; Dapunt O
Br J Cancer; 1997; 76(12):1646-51. PubMed ID: 9413956
[TBL] [Abstract][Full Text] [Related]
13. Levels of v5 and v6 CD44 splice variants in serum of patients with colorectal cancer are not correlated with pT stage, histopathological grade of malignancy and clinical features.
Zalewski B
World J Gastroenterol; 2004 Feb; 10(4):583-5. PubMed ID: 14966921
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of serum prostate-specific antigen in urologic cancers.
Takeuchi T; Kuriyama M; Fujihiro S; Fujimoto Y; Okano M; Nishiura T
J Surg Oncol; 1983 Oct; 24(2):157-60. PubMed ID: 6195484
[TBL] [Abstract][Full Text] [Related]
15. Soluble CD44 splice variants in metastasizing human breast cancer.
Martin S; Jansen F; Bokelmann J; Kolb H
Int J Cancer; 1997 Aug; 74(4):443-5. PubMed ID: 9291436
[TBL] [Abstract][Full Text] [Related]
16. Elevated serum soluble CD44 level in sarcoidosis.
Kasuga I; Minemura K; Nasu H; Hibi N; Tago H; Nagate A; Kunisawa A; Ohyashiki JH; Ohyashiki K
Int J Mol Med; 2000 Dec; 6(6):679-82. PubMed ID: 11078828
[TBL] [Abstract][Full Text] [Related]
17. Serum soluble CD44 levels for monitoring disease states in acute leukemia and myelodysplastic syndromes.
Nasu H; Hibi N; Ohyashiki JH; Hara A; Kubono K; Tsukada Y; Ando K; Iwama H; Hayashi S; Yahata N; Toyama K; Ohyashiki K
Int J Oncol; 1998 Sep; 13(3):525-30. PubMed ID: 9683788
[TBL] [Abstract][Full Text] [Related]
18. Tumor M2 pyruvate kinase in plasma of patients with urological tumors.
Roigas J; Schulze G; Raytarowski S; Jung K; Schnorr D; Loening SA
Tumour Biol; 2001; 22(5):282-5. PubMed ID: 11553857
[TBL] [Abstract][Full Text] [Related]
19. Increased soluble CD44 concentrations are associated with larger tumor size and lymph node metastasis in breast cancer patients.
Mayer S; zur Hausen A; Watermann DO; Stamm S; Jäger M; Gitsch G; Stickeler E
J Cancer Res Clin Oncol; 2008 Nov; 134(11):1229-35. PubMed ID: 18438684
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of soluble CD44 in patients with breast and colorectal carcinomas and non-Hodgkin's lymphoma.
Lockhart MS; Waldner C; Mongini C; Gravisaco MJ; Casanova S; Alvarez E; Hajos S
Oncol Rep; 1999; 6(5):1129-33. PubMed ID: 10425314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
